Aptiom

(eslicarbazepine)

PreclinicalSmall molecule

Sumitomo Pharma America, Inc.

Aptiom is one of 20 small molecule programs targeting Partial Epilepsy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Partial EpilepsyActive, not recruiting

Partial EpilepsyPreclinical

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Partial Epilepsy

#DrugCompanyPhaseTrials

Keppra

UCB

Approved

2 2

Trileptal

Novartis

Approved

1 3

Vimpat

UCB

Approved

1 4

Depakote

AbbVie

Approved

—5

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 6

Zonegran

AAzurity Pharmaceuticals

Approved

3 7

Fycompa

CCatalyst Biosciences

Approved

—8

Neurontin

VViatris Specialty LLC

Fintepla

Benemid

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Partial Epilepsy1 trial

Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

Completed· GSK logo

GSK··NCT01587339·6,498 enrolled

Adult1 trial

Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults

Completed·SStanford University·Phase 4·NCT02912364·46 enrolled

Regulatory

FDA Approval Timeline[4]

Nov 8, 2013

APTIOM

NDA NDA022416

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for eslicarbazepine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — eslicarbazepine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for eslicarbazepine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022416). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Aptiom. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Sumitomo Pharma America, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Sumitomo Pharma America, Inc.

Patent Landscape[5]

Patent Cliff

Sep 13, 2028

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9643929Apr 21, 2026

9206135Apr 21, 2026

9763954Sep 13, 2028

9566244Oct 23, 2028

10912781Oct 23, 2028

2 more patents

8372431Apr 17, 2030

9750747Aug 24, 2032

Aptiom

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Partial Epilepsy1 trial

Adult1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News